Prognostic value of p53 and Ki-67 expression in resected or biopsy specimens of bile duct carcinoma

Oncology Reports

Volumn 10, Issue 5, 2003, Pages 1091-1096

  Murakami, Masateru ^a   Sasaki, Tamito ^a   Kuwada, Yukio ^a   Yamasaki, Souichirou ^a   Kuwahara, Kenichi ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Assessment of Ki 67 antigen expression; Bile duct carcinoma; Biopsy specimens; Percutaneous transhepatic cholangioscope (PTCS); Predicting the effectiveness of radiation therapy

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; BILE DUCT TUMOR; BIOPSY; BIOSYNTHESIS; CANCER INVASION; CARCINOMA; CELL DIFFERENTIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PROGNOSIS; SEX DIFFERENCE; TIME;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BIOPSY; CARCINOMA; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; SEX FACTORS; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2142857213     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.10.5.1091     Document Type: Article

References (31)

1. Peters IJ, Brock WA, Chapman JD, Wilson G and Fowler JF: Response predictors in radiotherapy: a review of research into radiobiologically based assays. Br J Radiol 22: 96-108, 1988.
2. Valente G, Orecchia R, Gandolfo S, Arnaudo M, Ragona R, Kerim S, et al: Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma? J Clin Pathol 47: 109-112, 1994. (Pubitemid 24095460)
3. Lee CS: Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and Ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract. Cancer 78: 1881-1887, 1996.
4. Bjork-Eriksson T, West CML, Cvetskovska E, Svensson M, Karlsson E, Magnusson B, et al: The lack of correlation between proliferation (Ki-67, PCNA, LI, Tpot), p53 expression and radiosensitivity for head and neck cancers. Br J Cancer 80: 1400-1404, 1999. (Pubitemid 29308609)
5. Shrestha ML, Miyake H, Kikutsuji T and Tashiro S: Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder. J Med Invest 45: 95-102, 1998. (Pubitemid 128501271)
6. Isobe M, Emmanuel BS, Givol D, Cren M and Croce CM: Location of the gene for human p53 tumor antigen to band 17p1. Nature 320: 84-85, 1986. (Pubitemid 16105254)
7. Launois B, Reding R, Lebeau G and Buard JL: Surgery for hilar cholangiocarcinoma: French experience in a collective survey of 552 extrahepatic bile duct cancers. J Hepatobiliary Pancreat Surg 7: 128-134, 2000.
8. Nakeeb A, Pitt HA and Sohn TA: Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224: 463-473, 1996.
9. Rijken AM, Umezawa A, van Gulik TM, Bosma A, Polak MM, Offerhaus GJ, et al: Prognostic value of cell proliferation (Ki-67 antigen) and nuclear DNA content in clinically respectable, distal bile duct carcinoma. Ann Surg Oncol 5: 699-705, 1998. (Pubitemid 28565721)
10. Foo ML, Gunderson LL, Bender CE and Buskirk SJ: External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 39: 929-935, 1997. (Pubitemid 27486082)
11. Eguchi N, Fujii K, Tsuchida A, Yamamoto S, Sasaki T and Kajiyama G: Cyclin E overexpression in human gallbladder carcinomas. Oncol Rep 6: 93-96, 1999.
12. Yamamoto S, Fujii K, Kitadai Y, Yamamoto SO, Tsuchida A and Kajiyama G: Expression of vascular endothelial growth factor in human gallbladder lesions. Oncol Rep 5: 1065-1069, 1998. (Pubitemid 28372561)
13. Iwao T, Tsuchida A, Hanada K, Eguchi N, Kajiyama G and Shimamoto F: Immunohistochimical detection of p53 protein as an adjunct in cytologic diagnosis from pancreatic duct brushings in mucin-producing tumors of the pancreas. Cancer Cytopathol 81: 163-171, 1997. (Pubitemid 28275307)
14. McCormick D, Chong H, Hobbs C and Hall PA: Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB-1. Histopathology 22: 355-360, 1993. (Pubitemid 23159796)
15. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715, 1984. (Pubitemid 14035254)
16. Cattoretti G, Becker M, Key G, Duchrow M, Schluter C, Galle J, et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357-363, 1992. (Pubitemid 23013251)
17. Yamada Y, Yamauchi H, Kakizaki K and Suzuki H: Expression of Ki-67 by monoclonal antibody MIB-1 in carcinoma of the middle and lower bile duct. Tohoku J Exp Med 177: 375-377, 1995.
18. Ming T, Wee A and Gangaraju CR: An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas. Cancer 74: 1542-1545, 1994. (Pubitemid 24302972)
19. Suto T, Sugai T, Nakamura S, Funato O, Nitta H, Sasaki R, et ai. Assessment of the expression of p53, MIB-1 (Ki-67 antigen), and argyrophilic organizer regions in carcinoma of the extrahepatic bile duct. Cancer 82: 86-95, 1998.
20. Horie S, Endo K, Kawasaki H and Terada T: Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features. Virchows Arch 437: 25-30, 2000. (Pubitemid 30446912)
21. Bouzubar N, Walker KJ and Griffiths K: Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59: 943-947, 1989. (Pubitemid 19155714)
22. Leaned E, Garland S, Seri G, Marui FA, Perinea G and Scampini S: PCNA and MIB1 in breast carcinoma correlation with clinical and biological variables. J Clin Pathol 45: 416-419, 1992.
23. Kawamura T, Goseki N, Koike M, Takizawa T and Endo M: Acceleration of proliferative activity of esophageal carcinoma with invasion beyond the mucosa. Cancer 77: 843-849, 1996.
24. Oya M, Yato T, Nagai E and Tsureyoshi M: Metastasizing intraluminal gastric carcinomas, well-differentiated type and proliferative nuclear antigen and Ki-67. Cancer 75: 926-935, 1995.
25. Lee YC, Song SY, Chung JB, Kang JK and Park IS: p53 Protein expression in extrahepatic bile duct cancer. Yonsei Med J 37: 112-117, 1996. (Pubitemid 126450974)
26. Diamantis I, Karamitopoulou E, Perentes E and Zimmermann A: p53 Protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: correlation with tumor grade and survival Hepatology 22: 774-779, 1995.
27. Suto T, Sugai T, Nakamura S, Uesugi N, Sasaki R, Kanno S, et al: Immunohistochemical detection of proliferating cell nuclear antigen and p53 expression in carcinoma of the extrahepatic bile duct. Oncology 54: 407-413, 1997. (Pubitemid 27321120)
28. Rijken AM, Offerhaus GJA, Polak MM, Gouma DJ and van Gulik TM: p53 expression as a prognostic determinant in resected distal bile duct carcinoma. Eur J Surg Oncol 25: 297-301, 1999. (Pubitemid 29261292)
29. Iwao T, Hanada K, Tsuchida A, Hirata M, Eguchi N and Kajiyama G: The establishment of a preoperative diagnosis of pancreatic carcinoma using cell specimens from pancreatic duct brushing with special attention to p53 mutations. Cancer 82: 1487-1494, 1998. (Pubitemid 28164994)
30. Niiyama H, Mizunoto K, Kusumoto M, Ogawa T, Suehara N, Shimura H, et al: Activation of telomerase and its diagnostic application in biopsy specimens from biliary tract neoplasms Cancer 85: 2138-2143, 1999. (Pubitemid 29215552)
31. Tomasz K, Michal J, Maria ZK, Teresa S and Krzysztof S: Immunohistochimically stained markers (p53, PCNA, bcl-2) in dysplastic lesions of the larynx. Cancer Lett 143: 23-28, 1999.